医学
多发性硬化
免疫学
生物制剂
肿瘤科
免疫疗法
内科学
梅德林
奥克列珠单抗
抗体疗法
临床试验
疾病
纳塔利祖玛
自身免疫性疾病
免疫系统
重症监护医学
作者
Ayano Matsuyoshi,Koji Shinoda,Hajime Takeuchi,Yukiko Inamori,Ryo Kurasawa,Keisuke Mizutani,Yuu‐ichi Kira,Kazunori Iwao,Mitsuru Watanabe,Katsuhisa Masaki,Noriko Isobe
标识
DOI:10.1016/j.msard.2026.108044
摘要
BACKGROUND: Biologics are highly efficacious in preventing relapses of anti-aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorders (NMOSD). However, real-world data regarding biologic switching and on-treatment breakthrough relapses remain limited. METHODS: We retrospectively investigated the treatment history of 163 patients with AQP4-IgG-positive NMOSD who visited our hospitals between 2000 and 2026. Biologic switching was defined as a transition within 2 months from one biologic to another treatment with a different therapeutic target. Among those who underwent biologic switching, reasons for switching and Expanded Disability Status Scale (EDSS) score at switching were assessed. Relapses occurring during biologic treatment other than rituximab and tocilizumab were also analyzed. RESULTS: A total of 91 (55.8%) patients received at least one biologic. Among them, 17 patients underwent biologic switching after a median treatment duration of 1.5 years. The most frequent transitions were satralizumab to inebilizumab (n = 5), satralizumab to ravulizumab (n = 3), and ravulizumab to inebilizumab (n = 3). Switching was primarily driven by adverse events in satralizumab-treated patients, and by treatment burden and individual circumstances in ravulizumab-treated patients. Breakthrough relapses were documented in 7 patients: 6 during 131.1 person-years of satralizumab (0.05 events/person-year) and one during 61.9 person-years of ravulizumab (0.02 events/person-year), whereas no relapses occurred during 40.0 person-years of inebilizumab. Two patients switched biologics following breakthrough relapses. CONCLUSIONS: Biologic switching was primarily driven by adverse events, treatment burden, and individual circumstances rather than inadequate disease control. Breakthrough relapses during biologic treatment were uncommon and did not always result in switching biologics.
科研通智能强力驱动
Strongly Powered by AbleSci AI